scholarly journals Strand Displacement Amplification and the Polymerase Chain Reaction for Monitoring Response to Treatment in Patients with Pulmonary Tuberculosis

1996 ◽  
Vol 173 (4) ◽  
pp. 934-941 ◽  
Author(s):  
T. J. Hellyer ◽  
T. W. Fletcher ◽  
J. H. Bates ◽  
W. W. Stead ◽  
G. L. Templeton ◽  
...  
2000 ◽  
Vol 124 (11) ◽  
pp. 1649-1652 ◽  
Author(s):  
Edward L. Chan ◽  
Ken Brandt ◽  
Karen Olienus ◽  
Nick Antonishyn ◽  
Greg B. Horsman

Abstract Objective.—The Becton Dickinson BDProbeTec ET System is a new semiautomated system using strand displacement amplification technology that simultaneously amplifies and detects Chlamydia trachomatis and Neisseria gonorrhoeae DNA. The strand displacement amplification products are hybridized with a fluorescent detector probe and are captured by a chemiluminescent assay in a microwell format. An amplification control is also included to monitor assay inhibition. This study evaluated the performance of the BDProbTec ET system in detecting C trachomatis and N gonorrhoeae in male and female urine specimens, calculated its ability to process large volumes of specimens, and determined the inhibition rate. Materials and Methods.—Eight hundred twenty-five male and 399 female urine specimens were tested for both C trachomatis and N gonorrhoeae with the BDProbeTec ET system, and results were compared with those of the Roche Amplicor Cobas system. All urine specimens were processed on both assays on the same day they were received, according to the manufacturers' instructions. Discrepant results were resolved by in-house polymerase chain reaction assays. Internal or amplification controls were also used in each specimen assay to monitor inhibition. The throughput of the BDProbTec ET system was further tested with 150 urine specimens on an 8-hour shift for 2 days. Results.—The overall sensitivity, specificity, positive predicative value, and negative predicative value for for detection of chlamydia were 95.3%, 99.3%, 95.9%, and 99.2% for strand displacement amplification and 95.9%, 98.3%, 90.6%, and 99.3% for the Roche Amplicor system. For detection of gonorrhea, these values were 100%, 99.7%, 88.2%, and 100% and 96.7%, 98.9%, 69%, and 99.9%, respectively. The overall inhibition rates for both strand displacement amplification and Roche Amplicor were less than 3.5%. The BDProbTec ET system was able to produce 150 results each for chlamydia and gonorrhea and the internal control within the 8-hour shift. Conclusions.—The performance characteristics of the BDProbeTec ET assay are similar to those of the Roche Amplicor polymerase chain reaction for detection of chlamydia and gonorrhea in male and female urine specimens. The system was able to produce 300 results in an 8-hour shift.


Respirology ◽  
2001 ◽  
Vol 6 (4) ◽  
pp. 305-309 ◽  
Author(s):  
NITIPATANA CHIERAKUL ◽  
ANGKANA CHAIPRASERT ◽  
NIPA TINGTOY ◽  
WIYADA ARJRATANAKUL ◽  
SA-NGA PATTANAKITSAKUL

Blood ◽  
1998 ◽  
Vol 92 (9) ◽  
pp. 3376-3380 ◽  
Author(s):  
Marie-Hélène Delfau-Larue ◽  
Sophie Dalac ◽  
Eric Lepage ◽  
Tony Petrella ◽  
Janine Wechsler ◽  
...  

Abstract Although mycosis fungoides (MF) is considered to be an indolent lymphoma, survival is highly influenced by TNM stage. At diagnosis, most MF patients present with early stage disease and a high probability of long-term survival. Treatment is generally directed towards skin lesions, and achievement and duration of complete responses are variable. A dominant T-cell clone is detectable in the cutaneous lesions of 60% of patients. The aim of this study was to determine whether the presence of a T-cell clonal population influences the clinical course of the disease after topical therapy. Cutaneous biopsies from 68 patients were histologically diagnosed as MF and T-cell clonality was analyzed by in vitro amplification of TCR-γ chain gene rearrangements (polymerase chain reaction γ [PCRγ]). After a median follow-up of 48 months, response to treatment was clinically assessed. Age, sex, duration of symptoms before diagnosis, type of cutaneous lesions (T stage), TNM stage, and PCRγ were evaluated as predictive factors of response to treatment in univariate and multivariate analyses. Univariate analysis demonstrated that T1 cutaneous lesions (P = .05) and PCRγ negativity (P = .007) were associated with a higher complete remission rate. Using multivariate analysis, T stage (relative risk, 3.13; P = .06) and PCRγ (relative risk, 4.4; P = .01) remained independent significant predictive parameters of response. In conclusion, T stage and cutaneous PCRγ at diagnosis are the two predictive parameters of treatment response for MF. Therefore, the cutaneous PCRγ findings should be considered in the analysis of future therapeutic trials. © 1998 by The American Society of Hematology.


2020 ◽  
Vol 80 (3) ◽  
pp. 298-300
Author(s):  
Daniel Camprubí ◽  
Aina Gomila ◽  
Maria D. Grijota-Camino ◽  
Laura Soldevila ◽  
Maria J. Luque ◽  
...  

2009 ◽  
Vol 48 (6) ◽  
pp. 725-732 ◽  
Author(s):  
J. Lucian Davis ◽  
Laurence Huang ◽  
Joseph A. Kovacs ◽  
Henry Masur ◽  
Patrick Murray ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document